Get more information about Hizentra®

Connect with us

Hizentra Connect℠ patient support program

Sign up online today

Call 1-877-355-4447

Mon–Fri, 8 AM–8 PM ET.
Couple sitting next to each other researching on a laptop

Why Hizentra

Hizentra FAQs

There’s a lot to take in.
Get the answers that can help

About Hizentra

Ig therapy is generally delivered in one of two ways. Intravenous Ig therapy, or IVIg, is administered into the vein by a medical professional. Patients with PI typically receive IVIg once every 3–4 weeks.

Hizentra is a subcutaneous Ig therapy, or “SCIg,” (pronounced “skigg”) and is infused into the fatty layer under the skin (not into a vein). With proper training, most patients can self-infuse Hizentra or receive assistance from a caregiver. For CIDP, Hizentra is infused weekly. For PI, Hizentra may be infused daily or up to every 2 weeks. Talk with your healthcare provider about the dosing option that's right for you.

View the benefits of Hizentra

As a 20% SCIg therapy, Hizentra has the highest concentration of immunoglobulin available in a SCIg treatment, so you can receive the IgG treatment while infusing a lower volume, which potentially could result in fewer needlesticks. Hizentra was specifically designed to deliver Ig levels in half the volume of 10% Ig products,* regardless of which dosing schedule you and your healthcare provider choose.

*Based on an equivalent dose in grams.

Hizentra can be stored at room temperature (up to 25°C [77°F]) for up to 30 months, up to the expiration date printed on the outer carton of the prefilled syringe or vial label. This means you don't have to worry about refrigerating Hizentra at home or when you are on the go.

The amount of Hizentra you infuse per month will not change, regardless of how often you infuse.

How long each infusion takes may vary based on a number of factors, including how often you infuse, the number of infusion sites you use, your infusion rate, and other factors. You and your doctor can decide what is best for you.

For PI, you can have infusions as often as every day up to every 2 weeks.

Learn about personalized treatment options

The most common side effects in the clinical trials for Hizentra include redness, swelling, itching, and/or bruising at the infusion site; headache; chest, joint or back pain; diarrhea; tiredness; cough; rash; itching; fever, nausea, and vomiting. These are not the only side effects possible. Tell your doctor about any side effects that you may experience.

Learn about the safety profile of Hizentra

Hizentra is the first and only Ig available in prefilled syringes. While vials may still be available, prefilled syringes may be a convenient option for some people. Prefilled syringes may also simplify the set-up and transfer of Hizentra for those who have difficulty drawing from vials.

Your doctor can help you decide whether prefilled syringes are right for you.

Self-Infusion Info

That depends on the schedule that you and your doctor decide is best for you. Hizentra gives you protection with dosing options for PI that range from once a day to once every 2 weeks.

You and your doctor can choose your Hizentra dosing treatment plan based on:

  • Your routine
  • How much medicine per infusion
  • How long infusions take
  • How many infusion sites
Learn how you and your doctor can personalize your dosing and administration

A Hizentra dose may be infused into as many as 8 infusion sites simultaneously. In clinical trials, PI patients generally used 4 or fewer infusion sites per infusion, while CIDP patients most often used 4.

The number and location of infusion sites depend on the volume of the total dose. Infusion sites should be at least 2 inches apart. Change the actual site of infusion with each administration. New sites should be at least 1 inch from a previous site.

Recommended infusion sites include the thighs, upper arms, abdomen, and side of upper leg/hip. Ask your doctor or specialty pharmacy how many infusion sites are right for you.

Learn more about infusing with Hizentra

Most patients/caregivers can be trained to infuse. However, self-administration should be done only after you go through training and perform a successful demonstration in front of a healthcare professional.

You can always ask your healthcare professional questions about self-administration, especially if you need a refresher or if your infusion regimen has recently changed.

Learn how to self-administer

If your doctor signs you up for the Free Trial, you may be able to receive a 4-week supply of Hizentra and infusion equipment at no cost to you, plus free at-home visits by a trained nurse to help you learn to self-infuse.

See what the Free Trial has to offer Review tips for getting started

Yes. Partnering with one's PI healthcare provider is necessary for patients receiving Ig treatment. Regular visits with your PI healthcare provider are an important part of your therapy program.

At each visit, your PI healthcare provider will evaluate your dose and your response to treatment and address any concerns you may have.

It's important to bring your Hizentra therapy journal or send infusion records via the Hizentra app to share with your PI healthcare provider.

Review tips for getting started

Supplies needed for self-infusion of Hizentra include:

  • An infusion pump and any adapters (if required)
  • Infusion administration tubing
  • Subcutaneous needle set(s)
  • Pump-compatible syringe(s)
  • Transfer device or needle(s)
  • Gauze and tape, or transparent dressing Syringe-to-syringe transfer device (tip-to-tip connector)
  • Sharps container
  • Alcohol wipes
  • Antiseptic skin preps

CSL Behring does not provide or endorse specific pumps, needles, or supplies. Talk to your doctor or specialty pharmacy about which supplies are right for you.

Review tips for getting started Get your Welcome Kit

For weekly infusions, it can take about 1 to 2 hours to complete an infusion; however, this time may be shorter or longer depending on the dose and frequency your doctor has prescribed for you. Your experience may vary depending on a number of factors, including number of infusion sites, the rate of infusion, tubing, and how well you tolerate the treatment.

Talk with your PI healthcare provider about which option is best for you. For PI, several dosing schedules (from daily to once every 2 weeks) are available. Your doctor will work with you to find the dosing schedule that works best for you.

Review tips for getting started

For Pl patients

Your initial rate should not exceed 15 mL/hour/site, but can then be increased to 25 mL/hour/site depending on how you feel.

For CIDP patients

Your initial rate should not exceed 20 mL/hour/site, but can then be increased to 50 mL/hour/site depending on how you feel.

Throughout your self-infusion journey it's important to check in with your doctor or specialty pharmacy in order to discuss any necessary adjustments based on how you tolerate your infusions.

Review tips for getting started

Support & Resources

We are working to have Hizentra covered by as many health insurance formularies as possible. 95% of people with insurance are covered for Hizentra. Hizentra Connect℠ can also help you by doing a full benefits investigation to help you understand your options and how much they cost, identify managed care reimbursement opportunities, and talk to you about financial assistance if you're uninsured.

Hizentra is covered under Medicare Part B for CIDP and some types of PI.* Get the convenience of self-infused Hizentra, covered under the same benefit category as IVIg.† Medicare Part B coverage means lower out-of-pocket costs for you than with Part D, covering pump, supplies, medication, and nurse training.

We can help, even if Medicare Part B wasn't an option before. To learn more or start your enrollment online, call 1-877-355-4447, Monday-Friday, 8 AM to 8 PM ET.

*100% coverage for those with Medicare Part B and a Medigap plan after Part B annual deductible is met.

†Coverage of IVIg when administered in a clinical setting.

The cost of any treatment, including Hizentra, depends on a number of factors, including insurance status and the insurer's copay/coinsurance policy. The actual out-of-pocket cost to a patient will depend on their individual prescription and medical coverage.

For those who cannot afford their treatment, CSL Behring is committed to providing appropriate resources to ensure patients can begin and/or remain on their therapy. These include:

Continued Treatment After Insurance Loss - This program may be able to help you continue to receive treatment even if you experience a lapse in third-party private health insurance. Eligible patients earn points for Hizentra that you can use to secure medicine should you have a lapse in your third-party private health insurance. It is free and features easy enrollment and participation.*

Protection if you lose insurance

Copay Support Program - Most eligible people with commercial insurance pay $0 in out-of-pocket expenses for Hizentra†

Copay Support

Patient Assistance Program - Offers help if you are uninsured or underinsured, or otherwise can't afford Hizentra therapy. For more information, including program terms and conditions, call the Hizentra Connect℠ resource center, CSL Behring's single source for information about immunoglobulin therapies, at 1-877-355-4447, Monday-Friday, 8 AM to 8 PM ET.

*Enrollment required. Subject to terms and conditions. For the Assurance Program, visit www.csl.com/patients-public-health/patient-support-and-organizations/csl-behring-usa-support-and-assistance-programs.

†Subject to terms and conditions of the Copay Support Program. To read the full terms and conditions, click here. CSL Behring reserves the right to rescind, revoke, or amend the program at any time without notice.

If you and your doctor have decided you're ready to try Hizentra, you may be able to get a 1-month supply of medicine, infusion equipment, and in-home nurse training for free.

To apply for this program, ask your doctor to call Hizentra Connect℠ to see if you are eligible. For more information, call 1-877-355-4447, Monday-Friday, 8 AM to 8 PM ET.

Learn more

The Hizentra app means your infusion log is never farther away than your phone! The Hizentra app allows you to schedule personalized infusion reminders and track your infusion details from the palm of your hand. Tracking your infusions allows you to share your detailed history with your doctor and make any necessary changes to your therapy and personalize treatment to your specific responses and needs.

If you currently use the MyHizentra® Infusion Manager app, you will be transferred to the new Hizentra app during regular app updates. Upon launching the new app, current MyHizentra® Infusion Manager app users will be asked to confirm their profile so it can be migrated seamlessly into the new app.

Download the Hizentra app and start tracking today

Apple, the Apple logo, iPad, and iPhone are trademarks of Apple Inc., registered in the U.S. and other countries. App Store is a service mark of Apple Inc. By clicking the link or scanning the QR code above, you will be taken to a website hosted by Apple.

Android and Google Play are trademarks of Google Inc. By clicking the link or scanning the QR code above, you will be taken to a site hosted by Google Inc.

If you are a Hizentra patient or caregiver, you can sign up for one our local educational events near you. Hear from PI experts and other patients sharing their personal experiences.

You can also Connect With A Patient Advocate. This unique program from CSL Behring offers patients and caregivers the opportunity to and share their experience firsthand.*

Discover additional programs available to you

*Patient advocates are not healthcare providers or medical experts. For medical questions, please contact your physician. Voice2Voice advocates are compensated by CSL Behring LLC for their time and/or expenses.

Contact Hizentra Connect℠, who will conduct a full benefits investigation and assist in resolving the problem.

Several patient organizations have websites with information that may be helpful. Patients with PI can visit the Immune Deficiency Foundations (IDF) website, a global patient organization for patients with PI.

Connect with real Hizentra patients

Connect withreal Hizentra patients

Important Safety Information

WARNING: Thrombosis (blood clots) can occur with immune globulin products, including Hizentra. Risk factors can include: advanced age, prolonged immobilization, a history of blood clotting or hyperviscosity (blood thickness), use of estrogens, installed vascular catheters, and cardiovascular risk factors.

If you are at high risk of blood clots, your doctor will prescribe Hizentra at the minimum dose and infusion rate practicable and will monitor for signs of clotting events and hyperviscosity. Always drink sufficient fluids before infusing Hizentra.

See your doctor for a full explanation, and the full prescribing information for complete boxed warning.

Hizentra®, Immune Globulin Subcutaneous (Human), 20% Liquid, is a prescription medicine used to treat:

  • Primary immune deficiency (PI) in patients 2 years and older
  • Chronic inflammatory demyelinating polyneuropathy (CIDP) in adults

Treatment with Hizentra might not be possible if your doctor determines you have hyperprolinemia (too much proline in the blood), or are IgA-deficient with antibodies to IgA and a history of hypersensitivity. Tell your doctor if you have previously had a severe allergic reaction (including anaphylaxis) to the administration of human immune globulin. Tell your doctor right away or go to the emergency room if you have hives, trouble breathing, wheezing, dizziness, or fainting. These could be signs of a bad allergic reaction.

Inform your doctor of any medications you are taking, as well as any medical conditions you may have had, especially if you have a history of diseases related to the heart or blood vessels, or have been immobile for some time. Inform your physician if you are pregnant or nursing, or plan to become pregnant.

Infuse Hizentra under your skin only; do not inject into a blood vessel.

Self-administer Hizentra only after having been taught to do so by your doctor or other healthcare professional, and having received dosing instructions for treating your condition.

Immediately report to your physician any of the following symptoms, which could be signs of serious adverse reactions to Hizentra:

  • Reduced urination, sudden weight gain, or swelling in your legs (possible signs of a kidney problem).
  • Pain and/or swelling or discoloration of an arm or leg, unexplained shortness of breath, chest pain or discomfort that worsens on deep breathing, unexplained rapid pulse, or numbness/weakness on one side of the body (possible signs of a blood clot).
  • Bad headache with nausea; vomiting; stiff neck; fever; and sensitivity to light (possible signs of meningitis).
  • Brown or red urine; rapid heart rate; yellowing of the skin or eyes; chest pains or breathing trouble; fever over 100°F (possible symptoms of other conditions that require prompt treatment).

Hizentra is made from human blood. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent and its variant (vCJD), cannot be completely eliminated.

The most common side effects in the clinical trials for Hizentra include redness, swelling, itching, and/or bruising at the infusion site; headache; chest, joint or back pain; diarrhea; tiredness; cough; rash; itching; fever, nausea, and vomiting. These are not the only side effects possible. Tell your doctor about any side effect that bothers you or does not go away.

Before receiving any vaccine, tell immunizing physician if you have had recent therapy with Hizentra, as effectiveness of the vaccine could be compromised.

Please see full prescribing information for Hizentra, including boxed warning and the patient product information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

You can also report side effects to CSL Behring's Pharmacovigilance Department at 1-866-915-6958.
View information about Hizentra for:
You are leaving the current website.

The site you are accessing is maintained by a third party over whom CSL Behring has no control. CSL Behring does not review, approve, or necessarily endorse viewpoints, inferences, or conclusions stated in or implied by the content of this site. CSL Behring is not responsible for third-party content or the consequences of your use thereof.

Do you want to continue?